Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.
Recent biochemical and pharmacological findings concerning tamoxifen (TMX) have proven that both the unchanged drug and the main metabolites, N-desmethyltamoxifen (NDT) and 4-hydroxytamoxifen (4OHT) are biologically active. An HPLC method based on on-line post-column UV irradiation with fluorescence detection is described. Optimized conditions allowed complete and rapid separation of TMX 4OHT, NDT and two other recently reported metabolites, Y and Z. This method was applied to plasma and cytosol drug and metabolite analyses. In plasma, from the moment of initial drug administration until the steady state (after 1 month or more of continuous oral TMX treatment), the values of NDT to TMX ratios were completely reversed: 22 to 215 in mean %, P less than 0.01. The presence of metabolites Y and Z is significant. 4OHT, hardly detectable at the first dose, was measured at the steady state with high interpatient variability. It is hypothesized that metabolite evolution with time may be due to auto-induction of drug metabolism. In cytosols, which were all obtained during continuous TMX treatment, the ratios between TMX and metabolites were comparable to those observed in plasma, but with greater interpatient variability. Metabolite Y was not detectable in cytosols. This variability was not linked to the levels of cytosolic oestradiol receptors before initiation of treatment.
D001943:Breast Neoplasms / Q000032:analysis* / Q000188:drug therapy / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D003600:Cytosol / Q000032:analysis; D005260:Female; D006801:Humans; D008722:Methods; D013629:Tamoxifen / Q000031:analogs & derivatives / Q000032:analysis* / Q000378:metabolism / Q000627:therapeutic use
D013629:Tamoxifen; C016601:afimoxifene; C052626:ICI 142269; C028787:N-desmethyltamoxifen